RU2006133320A - Соединения индазолкарбоксамида в качестве агонистов 5-нт4 рецепторов - Google Patents
Соединения индазолкарбоксамида в качестве агонистов 5-нт4 рецепторов Download PDFInfo
- Publication number
- RU2006133320A RU2006133320A RU2006133320/04A RU2006133320A RU2006133320A RU 2006133320 A RU2006133320 A RU 2006133320A RU 2006133320/04 A RU2006133320/04 A RU 2006133320/04A RU 2006133320 A RU2006133320 A RU 2006133320A RU 2006133320 A RU2006133320 A RU 2006133320A
- Authority
- RU
- Russia
- Prior art keywords
- azabicyclo
- amide
- carboxylic acid
- oct
- ethyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 43
- DITBWPUMEUDVLU-UHFFFAOYSA-N 1h-indazole-3-carboxamide Chemical compound C1=CC=C2C(C(=O)N)=NNC2=C1 DITBWPUMEUDVLU-UHFFFAOYSA-N 0.000 title 1
- 108091005482 5-HT4 receptors Proteins 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims abstract 25
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 17
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 12
- 239000001257 hydrogen Substances 0.000 claims abstract 12
- 150000003839 salts Chemical class 0.000 claims abstract 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 7
- 239000012453 solvate Substances 0.000 claims abstract 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 6
- 229910052736 halogen Inorganic materials 0.000 claims abstract 6
- 150000002367 halogens Chemical group 0.000 claims abstract 6
- 150000002431 hydrogen Chemical group 0.000 claims abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims abstract 2
- -1 4-acetylpiperazin-1-yl Chemical group 0.000 claims 47
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 39
- FHUPHXAYPNYFIU-UHFFFAOYSA-N 1-propan-2-ylindazole-3-carboxylic acid Chemical compound C1=CC=C2N(C(C)C)N=C(C(O)=O)C2=C1 FHUPHXAYPNYFIU-UHFFFAOYSA-N 0.000 claims 36
- 150000001408 amides Chemical class 0.000 claims 13
- 238000000034 method Methods 0.000 claims 7
- IHZRQQYHYALFRG-UHFFFAOYSA-N 1-propan-2-ylindazole-3-carboxamide Chemical compound C1=CC=C2N(C(C)C)N=C(C(N)=O)C2=C1 IHZRQQYHYALFRG-UHFFFAOYSA-N 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 5
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 4
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000001771 impaired effect Effects 0.000 claims 3
- 230000004899 motility Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 206010010774 Constipation Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- BHXVYTQDWMQVBI-UHFFFAOYSA-N 1h-indazole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=NNC2=C1 BHXVYTQDWMQVBI-UHFFFAOYSA-N 0.000 claims 1
- IEIAQSWMJMZELU-UHFFFAOYSA-N 5-fluoro-1-propan-2-ylindazole-3-carboxylic acid Chemical compound FC1=CC=C2N(C(C)C)N=C(C(O)=O)C2=C1 IEIAQSWMJMZELU-UHFFFAOYSA-N 0.000 claims 1
- 206010051153 Diabetic gastroparesis Diseases 0.000 claims 1
- 206010021518 Impaired gastric emptying Diseases 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 208000013617 idiopathic gastroparesis Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- OEQJOYQHIGIVTN-UHFFFAOYSA-N tert-butyl nonanoate Chemical class CCCCCCCCC(=O)OC(C)(C)C OEQJOYQHIGIVTN-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229910052723 transition metal Inorganic materials 0.000 claims 1
- 150000003624 transition metals Chemical class 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54570204P | 2004-02-18 | 2004-02-18 | |
| US60/545,702 | 2004-02-18 | ||
| PCT/US2005/005070 WO2005080389A1 (en) | 2004-02-18 | 2005-02-17 | Indazole-carboxamide compounds as 5-ht4 receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006133320A true RU2006133320A (ru) | 2008-03-27 |
Family
ID=34886184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006133320/04A RU2006133320A (ru) | 2004-02-18 | 2005-02-17 | Соединения индазолкарбоксамида в качестве агонистов 5-нт4 рецепторов |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7351704B2 (https=) |
| EP (1) | EP1718643A1 (https=) |
| JP (1) | JP2007523175A (https=) |
| KR (1) | KR20060132727A (https=) |
| CN (1) | CN1922175A (https=) |
| AR (1) | AR047681A1 (https=) |
| AU (1) | AU2005214368A1 (https=) |
| BR (1) | BRPI0507791A (https=) |
| CA (1) | CA2553696A1 (https=) |
| IL (1) | IL177059A0 (https=) |
| MA (1) | MA28435B1 (https=) |
| NO (1) | NO20064156L (https=) |
| RU (1) | RU2006133320A (https=) |
| TW (1) | TW200533348A (https=) |
| WO (1) | WO2005080389A1 (https=) |
| ZA (1) | ZA200606479B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2569733C2 (ru) * | 2010-02-12 | 2015-11-27 | Раквалиа Фарма Инк. | Агонисты 5-нт4-рецепторов для лечения деменции |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200533348A (en) * | 2004-02-18 | 2005-10-16 | Theravance Inc | Indazole-carboxamide compounds as 5-ht4 receptor agonists |
| US8309575B2 (en) | 2004-04-07 | 2012-11-13 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| US7728006B2 (en) * | 2004-04-07 | 2010-06-01 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| TWI351282B (en) | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
| US7399862B2 (en) * | 2004-11-05 | 2008-07-15 | Theravance, Inc. | 5-HT4 receptor agonist compounds |
| WO2006052889A2 (en) * | 2004-11-05 | 2006-05-18 | Theravance, Inc. | Quinolinone-carboxamide compounds |
| CA2588037A1 (en) * | 2004-12-22 | 2006-06-29 | Theravance, Inc. | Indazole-carboxamide compounds |
| WO2006088988A1 (en) * | 2005-02-17 | 2006-08-24 | Theravance, Inc. | Crystalline form of an indazole-carboxamide compound |
| CN101163701A (zh) * | 2005-03-02 | 2008-04-16 | 施万制药 | 作为5-ht4受体激动剂的喹啉酮化合物 |
| EP1902053B1 (en) * | 2005-06-07 | 2011-01-12 | Theravance, Inc. | Benzoimidazolone-carboxamide compounds as 5-ht4 receptor agonists |
| US20080262040A1 (en) * | 2005-10-25 | 2008-10-23 | Smithkline Beecham Corporation | Chemical Compounds |
| MY143574A (en) * | 2005-11-22 | 2011-05-31 | Theravance Inc | Carbamate compounds as 5-ht4 receptor agonists |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| CN101384588B (zh) * | 2006-02-16 | 2011-08-31 | 施万制药 | 制备5-ht4受体激动剂化合物的中间体的方法 |
| KR100812499B1 (ko) * | 2006-10-16 | 2008-03-11 | 이도훈 | 항경련제 |
| WO2008101728A1 (de) * | 2007-02-23 | 2008-08-28 | K.H.S. Pharma Holding Gmbh | Verfahren zur herstellung von azoniaspironortropinestern und von nortropan-3-on verbindungen |
| EP2241567A4 (en) * | 2008-02-13 | 2011-11-09 | Eisai R&D Man Co Ltd | Bicycloamine DERIVATIVE |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| WO2011092290A1 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
| EP2531490B1 (en) | 2010-02-02 | 2014-10-15 | Novartis AG | Cyclohexyl amide derivatives as crf receptor antagonists |
| AR086554A1 (es) | 2011-05-27 | 2014-01-08 | Novartis Ag | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
| KR20140041519A (ko) * | 2011-06-07 | 2014-04-04 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 인다졸-유도체 및 피롤로피리딘-유도체 및 그의 약제학적 용도 |
| JP2015525202A (ja) | 2012-05-03 | 2015-09-03 | ノバルティス アーゲー | グレリン受容体アゴニストとしての２，７−ジアザ−スピロ［４，５］デカ−７−イル誘導体のｌ−リンゴ酸塩およびその結晶形態 |
| JP2014133739A (ja) * | 2012-12-12 | 2014-07-24 | Dainippon Sumitomo Pharma Co Ltd | インダゾール誘導体またはピロロピリジン誘導体からなる医薬 |
| RS60804B1 (sr) * | 2014-08-16 | 2020-10-30 | Suven Life Sciences Ltd | Proces proizvodnje 1-izopropil-3-{5-[1-(3-metoksipropil)piperidin-4-il]-[1,3,4]oksadiazol-2-il}-1h-indazol oksalata u velikom obimu |
| CN112805282A (zh) * | 2019-09-12 | 2021-05-14 | 广东东阳光药业有限公司 | 吲唑-甲酰胺衍生物及其用途 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4321378A (en) | 1979-01-16 | 1982-03-23 | Delalande S.A. | 8-(5-Pyrimidinecarboxamide)nor-tropane derivatives |
| US4937247A (en) | 1985-04-27 | 1990-06-26 | Beecham Group P.L.C. | 1-acyl indazoles |
| GB8527052D0 (en) * | 1985-11-02 | 1985-12-04 | Beecham Group Plc | Compounds |
| HU895334D0 (en) | 1986-07-30 | 1990-01-28 | Sandoz Ag | Process for the preparation of nasal pharmaceutical compositions |
| US4948803A (en) | 1986-11-21 | 1990-08-14 | Glaxo Group Limited | Medicaments for treatment on prevention of withdrawal syndrome |
| GB8701022D0 (en) | 1987-01-19 | 1987-02-18 | Beecham Group Plc | Treatment |
| US5223511A (en) | 1987-09-23 | 1993-06-29 | Boehringer Ingelheim Italia S.P.A. | Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists |
| IT1231413B (it) | 1987-09-23 | 1991-12-04 | Angeli Inst Spa | Derivati dell'acido benzimidazolin-2-osso-1-carbossilico utili come antagonisti dei recettori 5-ht |
| IT1226389B (it) | 1988-07-12 | 1991-01-15 | Angeli Inst Spa | Nuovi derivati ammidinici e guanidinici |
| US5017573A (en) | 1988-07-29 | 1991-05-21 | Dainippon Pharmaceutical Co., Ltd. | Indazole-3-carboxylic acid derivatives |
| EP0410509A1 (en) | 1989-07-25 | 1991-01-30 | Duphar International Research B.V | New substituted 1H-indazole-3-carboxamides |
| JPH045289A (ja) | 1990-04-24 | 1992-01-09 | Hokuriku Seiyaku Co Ltd | アミド化合物 |
| JP3122671B2 (ja) | 1990-05-23 | 2001-01-09 | 協和醗酵工業株式会社 | 複素環式化合物 |
| HU211081B (en) | 1990-12-18 | 1995-10-30 | Sandoz Ag | Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same |
| CA2097815C (en) | 1990-12-28 | 2001-04-17 | Fumio Suzuki | Quinoline derivative |
| CA2116024A1 (en) | 1991-08-20 | 1993-03-04 | Francis David King | 5-ht4 receptor antagonists |
| US5552398A (en) | 1991-09-12 | 1996-09-03 | Smithkline Beecham P.L.C. | Azabicyclic compounds as 5-HT4 receptor antagonists |
| MX9305947A (es) | 1992-09-29 | 1994-06-30 | Smithkline Beecham Plc | Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen. |
| WO1994012497A1 (fr) | 1992-11-20 | 1994-06-09 | Taisho Pharmaceutical Co., Ltd. | Compose heterocyclique |
| TW251287B (https=) | 1993-04-30 | 1995-07-11 | Nissei Co Ltd | |
| GB9310582D0 (en) | 1993-05-22 | 1993-07-07 | Smithkline Beecham Plc | Pharmaceuticals |
| AU679336B2 (en) | 1994-02-28 | 1997-06-26 | Taisho Pharmaceutical Co., Ltd. | Heterocyclic compound |
| US5864039A (en) | 1994-03-30 | 1999-01-26 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzoic acid compounds and use thereof as medicaments |
| GB9406857D0 (en) | 1994-04-07 | 1994-06-01 | Sandoz Ltd | Improvements in or relating to organic compounds |
| JP3829879B2 (ja) | 1994-05-18 | 2006-10-04 | 大正製薬株式会社 | キノリンカルボン酸誘導体 |
| CA2160420A1 (en) | 1994-10-20 | 1996-04-21 | Haruhiko Kikuchi | 5-ht4 receptor agonists |
| JP3829880B2 (ja) | 1994-12-27 | 2006-10-04 | 大正製薬株式会社 | 化学中間体 |
| IT1275903B1 (it) | 1995-03-14 | 1997-10-24 | Boehringer Ingelheim Italia | Esteri e ammidi della 1,4-piperidina disostituita |
| US5654320A (en) | 1995-03-16 | 1997-08-05 | Eli Lilly And Company | Indazolecarboxamides |
| EP0829474B1 (en) | 1995-05-31 | 2003-04-09 | Nisshin Seifun Group Inc. | Indazole derivatives having monocyclic amino group |
| ES2109190B1 (es) | 1996-03-22 | 1998-07-01 | Univ Madrid Complutense | Nuevos derivados de bencimidazol con afinidad por los receptores serotoninergicos 5-ht /5-ht |
| IT1291569B1 (it) | 1997-04-15 | 1999-01-11 | Angelini Ricerche Spa | Indazolammidi come agenti serotoninergici |
| TW548103B (en) | 1997-07-11 | 2003-08-21 | Janssen Pharmaceutica Nv | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives |
| US5914405A (en) | 1997-10-07 | 1999-06-22 | Eli Lilly And Company | Process for preparing 3-substituted indazoles |
| US6069152A (en) * | 1997-10-07 | 2000-05-30 | Eli Lilly And Company | 5-HT4 agonists and antagonists |
| FR2769915B1 (fr) | 1997-10-21 | 2000-10-13 | Synthelabo | Derives d'indazole tricycliques, leur preparation et leur application en therapeutique |
| IT1298271B1 (it) | 1998-02-18 | 1999-12-20 | Boehringer Ingelheim Italia | Esteri ed ammidi dell'acido 2-oxo-2,3-diidro-benzimidazol-1- carbossilico |
| EP1076055B1 (en) | 1998-04-28 | 2004-11-24 | Dainippon Pharmaceutical Co., Ltd. | 1- (1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds |
| AU758807B2 (en) | 1998-09-10 | 2003-03-27 | F. Hoffmann-La Roche Ag | Dihydrobenzodioxine carboxamide and ketone derivatives as 5-HT4 receptor antagonists |
| TW570920B (en) | 1998-12-22 | 2004-01-11 | Janssen Pharmaceutica Nv | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders |
| PE20001420A1 (es) | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
| FR2792318B1 (fr) | 1999-04-16 | 2001-06-15 | Synthelabo | Derives d'indazole, leur preparation et leur application en therapeutique |
| EP1173168A2 (en) | 1999-04-28 | 2002-01-23 | Respiratorius AB | Compound for use as a medicament for treatment of disorders involving bronchocontraction |
| ES2154605B1 (es) | 1999-09-14 | 2001-11-16 | Univ Madrid Complutense | Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3 |
| IT1313625B1 (it) | 1999-09-22 | 2002-09-09 | Boehringer Ingelheim Italia | Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina. |
| IT1313660B1 (it) | 1999-10-01 | 2002-09-09 | Dompe Spa | Procedimento stereoselettivo per la preparazione di endo-3-amminoazabicicloalcani. |
| WO2002036113A1 (en) | 2000-11-01 | 2002-05-10 | Respiratorius Ab | Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4) |
| US6624162B2 (en) | 2001-10-22 | 2003-09-23 | Pfizer Inc. | Imidazopyridine compounds as 5-HT4 receptor modulators |
| MXPA03000145A (es) | 2002-01-07 | 2003-07-15 | Pfizer | Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4. |
| EP1492789B1 (en) | 2002-04-08 | 2006-06-07 | Pfizer Limited | Tropane derivatives as ccr5 modulators |
| US6696468B2 (en) | 2002-05-16 | 2004-02-24 | Dainippon Pharmaceutical Co., Ltd. | (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor |
| MXPA05003065A (es) | 2002-09-20 | 2005-05-27 | Pfizer | Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht4. |
| DOP2003000703A (es) | 2002-09-20 | 2004-03-31 | Pfizer | Compuestos de imidazopiradina como agonistas del receptor 5-ht4 |
| MXPA05011270A (es) | 2003-04-21 | 2006-01-24 | Pfizer | Compuestos de imidazopiridina que tienen actividad agonista del receptor 5-ht4 y actividad antagonista del receptor 5-ht3. |
| EP1641783B1 (en) | 2003-06-19 | 2012-03-28 | Janssen Pharmaceutica NV | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists |
| JO2478B1 (en) | 2003-06-19 | 2009-01-20 | جانسين فارماسوتيكا ان. في. | (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists |
| KR100738784B1 (ko) | 2003-09-03 | 2007-07-12 | 화이자 인코포레이티드 | 5-ｈｔ4 수용체 효능 활성을 갖는 벤즈이미다졸론 |
| BRPI0416813A (pt) | 2003-11-24 | 2007-03-06 | Pfizer | compostos de ácido quinolonacarboxìlico com atividade agonista do receptor 5-ht4 |
| ES2299995T3 (es) | 2004-01-29 | 2008-06-01 | Pfizer, Inc. | Derivados de 1-isopropil-2-oxo-1,2-dihidropiridina-3-carboxamida con actividad agonista de receptor 5-ht4. |
| TW200533348A (en) * | 2004-02-18 | 2005-10-16 | Theravance Inc | Indazole-carboxamide compounds as 5-ht4 receptor agonists |
| US7399862B2 (en) * | 2004-11-05 | 2008-07-15 | Theravance, Inc. | 5-HT4 receptor agonist compounds |
-
2005
- 2005-02-15 TW TW094104343A patent/TW200533348A/zh unknown
- 2005-02-17 AU AU2005214368A patent/AU2005214368A1/en not_active Abandoned
- 2005-02-17 CN CNA200580005307XA patent/CN1922175A/zh active Pending
- 2005-02-17 CA CA002553696A patent/CA2553696A1/en not_active Abandoned
- 2005-02-17 US US11/060,195 patent/US7351704B2/en active Active
- 2005-02-17 EP EP05723216A patent/EP1718643A1/en not_active Withdrawn
- 2005-02-17 WO PCT/US2005/005070 patent/WO2005080389A1/en not_active Ceased
- 2005-02-17 BR BRPI0507791-5A patent/BRPI0507791A/pt not_active IP Right Cessation
- 2005-02-17 KR KR1020067019088A patent/KR20060132727A/ko not_active Withdrawn
- 2005-02-17 JP JP2006554207A patent/JP2007523175A/ja active Pending
- 2005-02-17 RU RU2006133320/04A patent/RU2006133320A/ru not_active Application Discontinuation
- 2005-02-17 AR ARP050100560A patent/AR047681A1/es unknown
-
2006
- 2006-07-25 IL IL177059A patent/IL177059A0/en unknown
- 2006-08-03 ZA ZA200606479A patent/ZA200606479B/en unknown
- 2006-08-18 MA MA29276A patent/MA28435B1/fr unknown
- 2006-09-14 NO NO20064156A patent/NO20064156L/no not_active Application Discontinuation
-
2008
- 2008-02-04 US US12/012,579 patent/US7674908B2/en not_active Expired - Lifetime
-
2010
- 2010-01-19 US US12/689,763 patent/US8044045B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2569733C2 (ru) * | 2010-02-12 | 2015-11-27 | Раквалиа Фарма Инк. | Агонисты 5-нт4-рецепторов для лечения деменции |
Also Published As
| Publication number | Publication date |
|---|---|
| NO20064156L (no) | 2006-11-10 |
| CA2553696A1 (en) | 2005-09-01 |
| JP2007523175A (ja) | 2007-08-16 |
| TW200533348A (en) | 2005-10-16 |
| US20050197335A1 (en) | 2005-09-08 |
| CN1922175A (zh) | 2007-02-28 |
| WO2005080389A1 (en) | 2005-09-01 |
| IL177059A0 (en) | 2006-12-10 |
| US20080146807A1 (en) | 2008-06-19 |
| US20100261716A1 (en) | 2010-10-14 |
| AU2005214368A1 (en) | 2005-09-01 |
| AR047681A1 (es) | 2006-02-01 |
| EP1718643A1 (en) | 2006-11-08 |
| BRPI0507791A (pt) | 2007-07-17 |
| MA28435B1 (fr) | 2007-02-01 |
| ZA200606479B (en) | 2008-01-30 |
| US7351704B2 (en) | 2008-04-01 |
| US8044045B2 (en) | 2011-10-25 |
| US7674908B2 (en) | 2010-03-09 |
| KR20060132727A (ko) | 2006-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006133320A (ru) | Соединения индазолкарбоксамида в качестве агонистов 5-нт4 рецепторов | |
| JP2007523175A5 (https=) | ||
| JP4796552B2 (ja) | ムスカリン性アセチルコリン受容体アンタゴニスト | |
| US11548887B2 (en) | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | |
| RU2006139053A (ru) | Хинолинонкарбоксамидные соединения в качестве агонистов 5-ht4 рецепторов | |
| US7902220B2 (en) | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | |
| RU2007128061A (ru) | Индазол-карбоксамидные соединения | |
| AR019478A1 (es) | Ligandos derivados de piperidina de alta afinidad para el receptor de nociceptina orl-1, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos. | |
| JP2007532546A5 (https=) | ||
| SK16698A3 (en) | (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)- -1-propanolmethanesulfonate trihydrate | |
| JP5042028B2 (ja) | キノリノン−カルボキサミド化合物 | |
| JP2008518965A5 (https=) | ||
| JPH10316567A (ja) | 過敏性腸症候群の症状の治療用のｎｋ−１受容体アンタゴニスト | |
| JP2009512624A5 (https=) | ||
| RU2007116950A (ru) | Производные тиенопиридинона и способы лечения | |
| Mustazza et al. | Nociceptin/orphanin FQ peptide (NOP) receptor modulators: an update in structure-activity relationships | |
| WO2003066004A2 (en) | Therapeutic compounds | |
| AU2007203078B2 (en) | Muscarinic acetylcholine receptor antagonists | |
| EP0873124A1 (en) | A method of treating hypercholesterolemia and related disorders | |
| HRP950549A2 (en) | A method of treating urinary bladder disfunctions | |
| JP2009516745A5 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20101013 |